問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Surgery

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Digestive System Department

更新時間:2023-09-19

吳教恩
  • Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

132Cases

2015-12-01 - 2026-12-31

Phase II

A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
8Sites

Recruiting8Sites

2024-05-21 - 2027-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-11-01 - 2022-03-11

Phase II

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors
  • Condition/Disease

    Non Small Cell Lung Cancer / Urothelial Cancer / Renal Cell Carcinoma / Hepatocellular Carcinoma / Melanoma

  • Test Drug

    INCB086550

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2021-05-31 - 2024-12-31

Phase III

A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation
  • Condition/Disease

    Non Small-cell Lung Cancer

  • Test Drug

    AMG 510 (Sotorasib)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2019-11-01 - 2023-01-31

Phase II/III

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cance
  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Bintrafusp alfa (M7824)

Participate Sites
7Sites

Recruiting7Sites

2021-11-15 - 2024-03-15

Phase I

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer
  • Condition/Disease

    Small Cell Lung Carcinoma

  • Test Drug

    AMG 757

Participate Sites
3Sites

Recruiting3Sites

2022-07-01 - 2028-01-24

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-11-01 - 2027-03-20

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-25 - 2025-10-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-12-01 - 2025-01-25

Phase III

A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
  • Condition/Disease

    Gastric Cancer,Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Bemarituzumab (AMG 552, FPA144)

Participate Sites
6Sites

Recruiting6Sites